BACKGROUND Rheumatoid Arthritis is a chronic disease and a leading cause of disability in people with advancing age. Disease modifying antirheumatic drugs have become the mainstay of management in rheumatoid arthritis. Among these drugs, methotrexate the most f r e q u e n t l y u s e d a g e n t h a s a p r o v e n anti-inflammatory action and is known to slow down the progression of the disease. Hence the present study is undertaken to evaluate the effect of methotrexate on the oxidant and antioxidant status in patients with rheumatoid arthritis on methotrexate.
METHODS
A total of 40 rheumatoid arthritis patients and 40 controls were enrolled for the study. The rheumatoid arthritis patients were further divided into patients on methotrexate (group I) and patients without methotrexate (group II). The lipid peroxidation index -Malondialdehyde and total antioxidant activity, superoxide dismutase and glutathione levels were analyzed in all the participants. RESULTS A significant increase in total antioxidant activity (p = 0.048) and decrease in lipid peroxidation (p = 0.04) was found in methotrexate treated arthritis patients compared to patients without methotrexate.A significant negative correlation (p=0.01) was found between MDA and total antioxidant activity in both groups of patients whereas, the antioxidant enzyme superoxide dismutase was positively correlated with lipid peroxide levels.
CONCLUSION
In conclusion low dose methotrexate seems to act as an effective anti-inflammatory drug and may also play an important role in minimizing the oxidative stress in rheumatoid arthritis. Serum total antioxidant activity is significantly raised in subjects with altered liver function profile. The focus of RA is the synovial lining, a highly vascularised tissue which surrounds the bones of the joint. Many reports suggest that lipid peroxidation product, malondialdehyde (MDA) a 3-carbon dialdehyde, which can form cross linkages in proteins is increased both in plasma and synovial fluid of patients with RA. Though RA has been categorized as a connective tissue disease and not recognized as a disease of oxidative stress, growing evidence suggests that production of free radicals within the inflamed joint can produce autoimmune phenomena and connective tissue destruction 3, 4 . Traditionally treatment of RA starts with non -steroidal anti-inflammatory drugs and/or corticosteroids. Then in later stage as the disease progresses, disease-modifying antirheumatic drugs (DMARDs) are added to the patient treatment regime. But recently, studies have shown that DMARDs alter the disease course playing a significant role in slowing the joint destruction. So treatment modalities have changed with patients been started early on with DMARDs. A number of DMARDs exist, of which low dose methotrexate is the most frequent and first choice. Other commonly used drugs are sulfasalazine, leflunomide, gold salts, antimalarial chloroquinine and azathioprine. Some of these drugs have been shown to possess an inhibitory effect on reactive oxygen species production 5, 6 . So the aim of the present study is to elucidate the possible effect of DMARD -methotrexate on lipid peroxidation and antioxidant status in patients suffering from RA.
METHODS
The study group consisted of 40 patients between the ages 27 to 69 years of both sexes (26 females and 14 males). These patients were selected from rheumatology clinic of Kasturba Medical College hospital and other hospitals in Mangalore. All the patients fulfilled the ACR revised criteria used for diagnosis of RA 7 . The median disease duration was 5.4 years. Normal age and sex matched individuals were taken as controls. All subjects were informed about the objectives of the study and informed consent was obtained. Patients with acute exacerbation of the illness and those on corticosteroids were not included in the study but were on NSAID for pain relief. The study was approved by the institutional ethics committee.
The Study group of RA patients were grouped as follows: Group I -consisted of 20 RA patients treated with Methotrexate. Group II -consisted of 20 RA patients not treated with Methotrexate / DMARDs. 5ml venous blood was collected in vacutainers under aseptic precautions from both patients and controls. Plasma MDA was measured using the modified method of Satoh 8 and total antioxidant activity (TAA) by the method of Koracevic et al 9 . Superoxide Dismutase (SOD) was estimated by the method of Beauchamp and Fridovich 10 and whole blood glutathione (GSH) was determined by the method of Beutler et al 11 . Data were statistical analyzed by Unpaired t-test and Pearson's Correlation and expressed in terms of p value.
RESULTS
The marker of lipid peroxidation -MDA (p = 0.0001)was significantly increased in RA patients compared to controls. Whole blood GSH (p =0.005 ) & total antioxidant activity levels (p = 0.0001) were decreased significantly in RA patients compared to controls. Superoxide dismutase activity (p =0.005) was notably increased in RA patients compared to controls. There was a significant decrease in lipid peroxidation (p=0.04) in methotrexate treated RA patients (group I) compared to non-methotrexate treated RA patients (group II). Similarly the total antioxidant activity (p =0.048 )was also significantly increased in group I patients compared to group II patients. Whole blood glutathione and SOD levels were almost similar but numerically different in both the groups of patients (Table II) . A significant strong negative correlation was noted between the total antioxidant activity ( p =0.01) and MDA level whereas a positive correlation between the antioxidant enzyme SOD and MDA was noted in both groups of rheumatoid arthritis patients. The antioxidant GSH was also 12, 13 .These ROS also serve as important intracellular signaling molecules that amplify the synovial inflammation-proliferative response. Thus, the enhanced oxidative stress and decreased antioxidant status observed in RA patients indicate the potential for oxidative injury to joints and synovial membrane.
Low dose methotrexate has been proved as an effective drug in controlling the inflammatory manifestations of RA. This is attributed to the targeting of ROS producing centers of the stimulated inflammatory cells leading to their apoptosis. Thus inhibiting their interaction with the inflammatory joint synovium. Methotrexate also seems to reduce the production of pro-inflammatory cytokines and mediators of inflammation especially interleukin-6 and tumor necrosis factor -∝ 14 .The present study demonstrated that in RA patients' use of DMARDs is associated with decrease in inflammation and changes in lipid peroxidation levels.
The total antioxidant activity is a dynamic equilibrium, the cooperation of the antioxidants in the human serum. TAA is indicative of disturbance in the antioxidant system, a result of diminished individual anti-oxidants. Gutteridge JM has shown that patients with RA have altered protein pattern in their serum and synovial fluid, which influences the TAA of these fluids 15 .The observed changes in TAA in methotrexate treated RA patients may be due to better control of inflammation. Glutathione, a tri-peptide thiol is a natural reservoir of reductive capacity of the cell. It is one of the major endogenous antioxidant. It maintains the thiols of many proteins and reduced forms of other antioxidants such as ascorbic acid & ∝-tocopherol 16 . Superoxide dismutase (SOD) is another free radical scavenging enzyme enhances the otherwise slow spontaneous breakdown of superoxide, forming less toxic hydrogen peroxide which can then interact with GSH and ultimately lead to H 2 O and O 2 17 . Mn-SOD has been found inducible under condition of stress/ inflammation, through the activation of down stream signaling pathways 18 . Manish et al have reported a significant increase in SOD levels in RA patients on NSAIDs 19 .
In our study, RA patients of both group I and II showed significant increase in SOD and significant decrease in GSH in comparison with the controls. A non-significant and numerically different SOD and GSH levels were found among both the groups of RA patients. These non-significant changes in different parameters analyzed among group I and II patients in our study may be due to the small number of cases and difference in severity of illness in the patients.
It has been postulated that dietary intervention with vitamins may reduce oxidative stress and thereby reduce the disease related morbidity and mortality associated with the disorder. Antioxidant defenses limit the damages caused by oxidants, such as those formed during inflammation. In addition, in vitro studies and animal studies have shown that antioxidants also possess anti-inflammatory properties. This implies that anti-oxidative defense mechanisms are of particular importance for patients with RA
In conclusion low dose methotrexate seems to exert anti-inflammatory effects by acting at different levels of pathophysiological cascade. Though the exact mechanism of methotrexate action in RA still remains unclear, it definitely is an effective anti inflammatory drug that helps to contain the oxidative stress mediated injury in rheumatoid arthritis.
